Atıf İçin Kopyala
PAYDAŞ S., ERGİN M., SEYDAOĞLU G., ERDOĞAN Ş., Yavuz S.
LEUKEMIA RESEARCH, cilt.33, sa.12, ss.1627-1635, 2009 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
33
Sayı:
12
-
Basım Tarihi:
2009
-
Doi Numarası:
10.1016/j.leukres.2009.02.015
-
Dergi Adı:
LEUKEMIA RESEARCH
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.1627-1635
-
Anahtar Kelimeler:
Lymphoma, VEGF-A, VEGF-C, Cox-2, TSP-1, Survivin, EBV, Prognosis, Angiogenesis, Lymphangiogenesis, EPSTEIN-BARR-VIRUS, ENDOTHELIAL GROWTH-FACTOR, NON-HODGKINS-LYMPHOMA, CHRONIC LYMPHOCYTIC-LEUKEMIA, LATENT GENE-EXPRESSION, COLON-CANCER CELLS, N-TERMINAL DOMAIN, PROGNOSTIC-SIGNIFICANCE, VEGF-C, CYCLOOXYGENASE-2 EXPRESSION
-
Çukurova Üniversitesi Adresli:
Evet
Özet
Background: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of Non-Hodgkins lymphomas (NHL). The outcome of these patients shows a wide variation. We evaluated the effect of six biologic parameters including Cyclooxygenase-2 (Cox-2), Survivin, Epstein Barr Virus (EBV), Vascular Endothelial Growth Factor-A (VEGF-A), Vascular Endothelial Growth Factor-C (VEGF-C), Thrombospondin-1 (TSP-1) and clinical parameters.